X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs DISHMAN PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB DISHMAN PHARMA DR. REDDYS LAB/
DISHMAN PHARMA
 
P/E (TTM) x 34.8 25.1 138.9% View Chart
P/BV x 2.7 3.3 79.7% View Chart
Dividend Yield % 1.0 0.7 152.6%  

Financials

 DR. REDDYS LAB   DISHMAN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
DISHMAN PHARMA
Mar-16
DR. REDDYS LAB/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,397374 907.2%   
Low Rs2,560129 1,986.0%   
Sales per share (Unadj.) Rs856.5197.8 433.0%  
Earnings per share (Unadj.) Rs78.021.2 367.6%  
Cash flow per share (Unadj.) Rs139.934.7 402.9%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.70.8 84.5%  
Book value per share (Unadj.) Rs739.8179.9 411.3%  
Shares outstanding (eoy) m165.7480.69 205.4%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.51.3 273.3%   
Avg P/E ratio x38.211.9 321.9%  
P/CF ratio (eoy) x21.37.2 293.7%  
Price / Book Value ratio x4.01.4 287.8%  
Dividend payout %25.79.4 272.0%   
Avg Mkt Cap Rs m493,63220,306 2,431.0%   
No. of employees `00022.70.8 2,735.9%   
Total wages/salary Rs m31,0685,355 580.2%   
Avg. sales/employee Rs Th6,259.019,252.7 32.5%   
Avg. wages/employee Rs Th1,369.86,459.5 21.2%   
Avg. net profit/employee Rs Th569.72,064.1 27.6%   
INCOME DATA
Net Sales Rs m141,96115,961 889.5%  
Other income Rs m1,715265 646.2%   
Total revenues Rs m143,67616,226 885.5%   
Gross profit Rs m24,7224,103 602.5%  
Depreciation Rs m10,2661,091 941.3%   
Interest Rs m634944 67.1%   
Profit before tax Rs m15,5372,334 665.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3491 31,727.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,965624 475.5%   
Profit after tax Rs m12,9211,711 755.1%  
Gross profit margin %17.425.7 67.7%  
Effective tax rate %19.126.7 71.4%   
Net profit margin %9.110.7 84.9%  
BALANCE SHEET DATA
Current assets Rs m96,83711,018 878.9%   
Current liabilities Rs m84,1999,517 884.7%   
Net working cap to sales %8.99.4 94.7%  
Current ratio x1.21.2 99.3%  
Inventory Days Days73110 66.4%  
Debtors Days Days9835 280.4%  
Net fixed assets Rs m102,55216,304 629.0%   
Share capital Rs m829161 513.6%   
"Free" reserves Rs m121,79212,907 943.6%   
Net worth Rs m122,62114,516 844.8%   
Long term debt Rs m5,4494,189 130.1%   
Total assets Rs m218,16529,805 732.0%  
Interest coverage x25.53.5 734.8%   
Debt to equity ratio x00.3 15.4%  
Sales to assets ratio x0.70.5 121.5%   
Return on assets %6.28.9 69.7%  
Return on equity %10.511.8 89.4%  
Return on capital %12.917.5 73.6%  
Exports to sales %54.624.8 220.3%   
Imports to sales %9.43.7 250.3%   
Exports (fob) Rs m77,5203,956 1,959.5%   
Imports (cif) Rs m13,274596 2,226.1%   
Fx inflow Rs m81,6704,952 1,649.4%   
Fx outflow Rs m26,355697 3,782.3%   
Net fx Rs m55,3154,255 1,300.1%   
CASH FLOW
From Operations Rs m21,4442,786 769.6%  
From Investments Rs m-18,404-1,529 1,203.7%  
From Financial Activity Rs m-3,692-941 392.3%  
Net Cashflow Rs m-1,144316 -361.6%  

Share Holding

Indian Promoters % 25.5 61.4 41.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 3.7 145.9%  
FIIs % 35.3 12.7 278.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 22.1 69.2%  
Shareholders   75,885 46,261 164.0%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   FDC LTD.  UNICHEM LAB  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT & Power Stocks Lead(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.1% while the Hang Seng is down 0.4%.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


May 25, 2018 12:47 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS